HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Allergy · Antihistamine Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Allergy · Antihistamine Therapeutic Area Assessment

13 signals · 5 insights · 58 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 69%

Evidence

76 items

Sources

1

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Allergy · Antihistamine integrates 13 signals, 5 executive insights, and 58 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 21, 2026

    Unique Pharmaceutical Laboratories Recalls Cetirizine Hydrochloride Due to Ranitidine Contamination

    Unique Pharmaceutical Laboratories is recalling four lots of Cetirizine Hydrochloride Tablets due to cross contamination with Ranitidine.

    View detail
  2. signalJul 23, 2026

    FDA Grants AP Status for Azelastine Hydrochloride and Fluticasone Propionate

    The FDA has granted Abbreviated Approval (AP) status for ANDA208111, a combination of Azelastine Hydrochloride and Fluticasone Propionate.

    View detail
  3. signalJul 19, 2026

    FDA Approval for XYZAL ALLERGY 24HR Supplement Application

    The FDA has accepted the supplemental application for XYZAL ALLERGY 24HR, indicating a review of its active ingredient, levocetirizine dihydrochloride.

    View detail
  4. signalJul 19, 2026

    FDA Approves Supplemental Application for Children's Claritin

    The FDA has approved a supplemental application for Children's Claritin (loratadine) submitted by Bayer Healthcare.

    View detail
  5. regulatoryJul 23, 2026

    FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    Application NDA201194. Sponsor: VISTAPHARM LLC. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: OXYCODONE HYDROCHLORIDE.

    View detail
  6. regulatoryJul 23, 2026

    FDA AP — REMIFENTANIL HYDROCHLORIDE (SUPPL)

    Application ANDA206223. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: REMIFENTANIL HYDROCHLORIDE.

    View detail
  7. regulatoryJul 23, 2026

    FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)

    Application ANDA078306. Sponsor: RISING. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: VERAPAMIL HYDROCHLORIDE.

    View detail
  8. regulatoryJul 23, 2026

    FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)

    Application ANDA090279. Sponsor: RUBICON RESEARCH. Submission status: AP. Submission type: SUPPL. Review priority: UNKNOWN. Active ingredients: BUPRENORPHINE HYDROCHLORIDE.

    View detail
  9. insightJul 21, 2026

    Regulatory and Market Implications of Cetirizine Recall Due to Contamination

    The recall of Cetirizine Hydrochloride due to contamination with Ranitidine raises significant safety concerns that could undermine consumer trust in antihistamine products. This incident may prompt regulatory scrutiny and necessitate a reassessment of safety protocols across the sector. Regulatory context from FDA (Unique Pharmaceutical Laboratories (A Div.) supports the near-term read. Assessment grounded in 21 ranked evidence items (9 high-relevance).

    View detail
  10. insightJul 18, 2026

    Emerging Dietary Evidence Could Transform Allergy Prevention Strategies

    This study's findings could reshape dietary recommendations for pregnant women, influencing the prevention strategies for food allergies in infants. Pharma companies involved in allergy therapeutics should stay informed to adapt their product development and marketing strategies accordingly. Regulatory context from FDA (FDA AP — ZYRTEC ALLERGY (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (16 high-relevance).

    View detail
  11. insightJun 25, 2026

    Epinephrine Auto-injector Study May Reshape Competitive Landscape

    The ongoing study on epinephrine auto-injector needle depth is critical as it may reveal significant differences in device efficacy, impacting market positioning among manufacturers. Companies will need to adapt their product designs and marketing strategies based on the study's findings to maintain competitive advantage in the allergy treatment market. Regulatory context from FDA (FDA AP — NOREPINEPHRINE BITARTRATE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).

    View detail
  12. insightJun 24, 2026

    New Generic Entry for Diphenhydramine Hydrochloride Alters Antihistamine Market Dynamics

    The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments. Regulatory context from FDA (FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (9 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 5 risk-calibrated assessments for portfolio review. 58 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 6 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    77%

    Application NDA201194. Sponsor: VISTAPHARM LLC. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: OXYCODONE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — REMIFENTANIL HYDROCHLORIDE (SUPPL)

    77%

    Application ANDA206223. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: REMIFENTANIL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)

    77%

    Application ANDA078306. Sponsor: RISING. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: VERAPAMIL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)

    66%

    Application ANDA090279. Sponsor: RUBICON RESEARCH. Submission status: AP. Submission type: SUPPL. Review priority: UNKNOWN. Active ingredients: BUPRENORPHINE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — SOTALOL HYDROCHLORIDE (SUPPL)

    66%

    Application ANDA075725. Sponsor: RISING. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: SOTALOL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    72%

    Application NDA200535. Sponsor: GENUS LIFESCIENCES. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: OXYCODONE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • Regulatory and Market Implications of Cetirizine Recall Due to Contamination

    63%

    The recall of Cetirizine Hydrochloride due to contamination with Ranitidine raises significant safety concerns that could undermine consumer trust in antihistamine products. This incident may prompt regulatory scrutiny and necessitate a reassessment of safety protocols across the sector. Regulatory context from FDA (Unique Pharmaceutical Laboratories (A Div.) supports the near-term read. Assessment grounded in 21 ranked evidence items (9 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Dietary Evidence Could Transform Allergy Prevention Strategies

    80%

    This study's findings could reshape dietary recommendations for pregnant women, influencing the prevention strategies for food allergies in infants. Pharma companies involved in allergy therapeutics should stay informed to adapt their product development and marketing strategies accordingly. Regulatory context from FDA (FDA AP — ZYRTEC ALLERGY (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (16 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Epinephrine Auto-injector Study May Reshape Competitive Landscape

    67%

    The ongoing study on epinephrine auto-injector needle depth is critical as it may reveal significant differences in device efficacy, impacting market positioning among manufacturers. Companies will need to adapt their product designs and marketing strategies based on the study's findings to maintain competitive advantage in the allergy treatment market. Regulatory context from FDA (FDA AP — NOREPINEPHRINE BITARTRATE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).

    Source: Humanexa Insight

    View evidence

  • New Generic Entry for Diphenhydramine Hydrochloride Alters Antihistamine Market Dynamics

    66%

    The FDA's approval of a generic version of Diphenhydramine Hydrochloride by Annora Pharma introduces a new competitor in the antihistamine market. This could disrupt pricing and market share for established brands, necessitating strategic adjustments. Regulatory context from FDA (FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (9 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Kenvue Brands Strengthens Market Position with Zyrtec Hives Approval

    69%

    The FDA's approval of Zyrtec Hives represents a significant regulatory milestone for Kenvue Brands, enhancing their portfolio in the competitive allergy market. This approval could shift market dynamics, prompting competitors to reassess their strategies in allergy treatments. Regulatory context from FDA (FDA AP — XYZAL ALLERGY 24HR (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (10 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Unique Pharmaceutical Laboratories Recalls Cetirizine Hydrochloride Due to Ranitidine Contamination

    Safety Signal

  • FDA Grants AP Status for Azelastine Hydrochloride and Fluticasone Propionate

    Regulatory Approval

  • FDA Approval for XYZAL ALLERGY 24HR Supplement Application

    Regulatory Approval

  • FDA Approves Supplemental Application for Children's Claritin

    Regulatory Approval

  • Study on Maternal Diet Impact on Infant Peanut and Egg Allergy Development

    Trial Update

  • FDA Approves Supplemental Application for Children's Zyrtec Hives

    Regulatory Approval

  • FDA Grants AP Status for Levocetirizine Dihydrochloride ANDA205564

    Regulatory Approval

  • FDA Accepts Supplement for RYALTRIS by Glenmark

    Regulatory Approval

Insights

  • Regulatory and Market Implications of Cetirizine Recall Due to Contamination

    Allergy · Antihistamine

  • Emerging Dietary Evidence Could Transform Allergy Prevention Strategies

    Allergy · Food Allergy

  • Epinephrine Auto-injector Study May Reshape Competitive Landscape

    Allergy · Anaphylaxis

  • New Generic Entry for Diphenhydramine Hydrochloride Alters Antihistamine Market Dynamics

    Allergy · Antihistamine

  • Kenvue Brands Strengthens Market Position with Zyrtec Hives Approval

    Allergy · Antihistamine

Companies

  • Bayer

    13 signals

  • Sanofi

    11 signals

  • Macleods Pharmaceuticals

    10 signals

  • Annora Pharma

    6 signals

  • Glenmark

    2 signals

  • Chattem Sanofi

    2 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.